Perrigo CoPRGO +2.79%44 PS Ratio is 0.33 as of Jun. 28, 2026, which is 76% below its 10-year median of 1.38. GuruFocus rates PRGO with a GF Score™ of 44/100 and a GF Value™ of $25.00 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 949 Drug Manufacturers companies, Perrigo Co ranks better than 93.05% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Perrigo Co's share price is $9.95.
Perrigo Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $30.10. Hence, Perrigo Co's PS Ratio for today is 0.33.
Good Sign:
Perrigo Co PLC stock PS Ratio (=0.33) is close to 10-year low of 0.3.
The historical rank and industry rank for Perrigo Co's PS Ratio or its related term are showing as below:
PRGO'
s PS Ratio Range Over the Past 10 Years
Min: 0.3 Med: 1.38 Max: 2.74
Current: 0.33
During the past 13 years, Perrigo Co's highest PS Ratio was 2.74. The lowest was 0.30. And the median was 1.38.
PRGO's PS Ratio is ranked better than 93.05% of 949
companies
in the Drug Manufacturers industry
Industry Median: 2.2
vs PRGO: 0.33
Perrigo Co PLC revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Perrigo Co was -4.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -2.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 0.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -0.50% per year.
During the past 13 years, Perrigo Co's highest 3-Year average Revenue per Share Growth Rate was 17.50% per year. The lowest was -8.40% per year. And the median was 5.30% per year.
Back to Basics: PS Ratio
Perrigo Co (NYSE:PRGO) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Perrigo Co PS Ratio Related Terms
Perrigo Co PS Ratio Historical Data
* Premium members only.
The historical data trend for Perrigo Co's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perrigo Co PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Perrigo Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Perrigo Co's Share Price of today is $9.95. Perrigo Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $30.10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Perrigo Co (PRGO) has a PS Ratio of 0.33 as of Jun. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Perrigo Co and its competitors. This is 76% below median its historical median of 1.38. Over the past decade, Perrigo Co's PS Ratio has ranged from 0.30 to 2.74. According to the industry distribution chart, Perrigo Co ranks #66 out of 949 companies in the Drug Manufacturers industry, placing it in the top 7%.
Is Perrigo Co's PS Ratio too high?
Perrigo Co's current PS Ratio of 0.33 is 76% below median its 10-year median of 1.38. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 2.74. The Drug Manufacturers industry median PS Ratio is 2.20. Perrigo Co's value of 0.33 is 85% below this industry median. Based on the distribution chart, Perrigo Co ranks #66 out of 949 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Perrigo Co has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Perrigo Co's PS Ratio compare to XERS and PAHC?
According to the Drug Manufacturers industry distribution chart, Perrigo Co ranks #66 out of 949 companies for PS Ratio. This places Perrigo Co in the top 7% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.20. Perrigo Co's value of 0.33 is 85% below this benchmark. Historically, Perrigo Co's own PS Ratio has ranged from 0.30 to 2.74 over the past decade. While the company's 10-year median is 1.38 vs. the industry median of 2.20, Perrigo Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.20, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Perrigo Co's current PS Ratio of 0.33 is 85% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Perrigo Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perrigo Co's current PS Ratio is 0.33, which is 76% below median its own 10-year median of 1.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perrigo Co stock overvalued right now?
Based on GuruFocus' analysis, Perrigo Co (PRGO) is currently considered Possible Value Trap. The stock's GF Value™ is $25.00, compared to a current price of $9.95 — trading 60.2% below its estimated fair value. The current PS Ratio is 0.33, which is 76% below median its 10-year median of 1.38 and 85% below the Drug Manufacturers industry median of 2.20. Perrigo Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Perrigo Co (PRGO), the current PS Ratio is 0.33 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perrigo Co (PRGO) Overvalued in 2026?
Based on GuruFocus' analysis, Perrigo Co stock appears to be undervalued.
The current stock price of $9.95 is trading 60.2% below its estimated GF Value™ of $25.00.
GuruFocus considers Perrigo Co to be Possible Value Trap.
Key valuation signals for PRGO:
PS Ratio: 0.33 (76% below median its 10-year median of 1.38)
GF Value™: $25.00 vs. price of $9.95 (60.2% below fair value)
Industry Position: 85% below the Drug Manufacturers median (#66 of 949)
No single metric tells the full story. See the PRGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
44GF Score
Get the complete analysis for PRGO
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRGO has been successfully added to your 
